{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-081799","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.235375+00:00","generated_at":"2026-05-31T01:56:15.310819+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cadrenal Therapeutics posts updated presentation detailing Phase 3 plans for tecarfarin in LVAD and other indications","bullets":["Phase 3 trial planned for LVAD patients: 440 patients randomized 1:1 tecarfarin vs warfarin for 26 weeks.","Tecarfarin has FDA Orphan Drug Designation for LVAD and ESKD+AFib, and Fast Track for ESKD+AFib.","Cash $5.0M, no debt, market cap $14.2M as of 9/18/24; insider ownership 42%.","Phase 2/3 data showed tecarfarin achieved higher TTR (70% vs 67%, p=0.04) and fewer thrombotic events than warfarin.","Presentation also outlines targeted indications: MHV patients with difficult-to-control TTR or warfarin resistance."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-081799","json":"https://secwatch.observer/filing/0001213900-24-081799.json","markdown":"https://secwatch.observer/filing/0001213900-24-081799.md","text":"https://secwatch.observer/filing/0001213900-24-081799.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/0001213900-24-081799-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024081799/ea0215596-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:56:15.310819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}